We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

34 hedge funds and large institutions have $5.61M invested in Protalix BioTherapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

11% more call options, than puts

Call options by funds: $1.57M | Put options by funds: $1.42M

3% more funds holding

Funds holding: 33 → 34 (+1)

0.17% more ownership

Funds ownership: 9.51% → 9.68% (+0.17%)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

26% less capital invested

Capital invested by funds: $7.58M → $5.61M (-$1.97M)

Holders
34
Holders Change
+1
Holders Change %
+3.03%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
10
Closed
5
Calls
$1.57M
Puts
$1.42M
Net Calls
+$154K
Net Calls Change
-$178K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$643K
2
GCP
GSA Capital Partners
United Kingdom
+$387K
3
Group One Trading
Group One Trading
Illinois
+$66.1K
4
IWM
IHT Wealth Management
Illinois
+$50.5K
5
DC
Davenport & Co
Virginia
+$36.5K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$509K
2
Walleye Capital
Walleye Capital
New York
-$192K
3
Citadel Advisors
Citadel Advisors
Florida
-$138K
4
Walleye Trading
Walleye Trading
New York
-$82.1K
5
Renaissance Technologies
Renaissance Technologies
New York
-$57K
Name Holding Trade Value Shares
Change 		Change in
Stake
MIFH
26
Migdal Insurance & Financial Holdings
Israel
$5K +$6.08K +4,000 New
HI
27
Harbour Investments
Wisconsin
$4K +$4.56K +3,000 New
UBS Group
28
UBS Group
Switzerland
$3K +$591 +389 +20%
FDCDDQ
29
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.46K – – –
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$1K -$942 -620 -55%
CAPTRUST Financial Advisors
31
CAPTRUST Financial Advisors
North Carolina
$1K – – –
SPIA
32
Steward Partners Investment Advisory
New York
$1K – – –
TCWA
33
Ten Capital Wealth Advisors
Washington
$1K +$345 +227 +70%
Walleye Capital
34
Walleye Capital
New York
$293 -$192K -126,450 -36%
Renaissance Technologies
35
Renaissance Technologies
New York
– -$57K -30,075 Closed
TRCT
36
Tower Research Capital (TRC)
New York
– -$9K -4,658 Closed
RDWM
37
Red Door Wealth Management
Tennessee
– -$3K -2,000 Closed
Deutsche Bank
38
Deutsche Bank
Germany
– -$2K -873 Closed
GAM
39
Gemmer Asset Management
California
– -$2K -800 Closed
1
2

PLX Hedge Fund Activity: Q3 2021 in Review

34 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2021, worth a combined $5.61M — down 26% from $7.58M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PLX positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $643K. The largest seller was Bridgeway Capital Management, cutting an estimated $509K.

  • 34 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2021, up from 33 in Q2 2021.
  • Funds reported $5.61M of Protalix BioTherapeutics stock for Q3 2021, down 26% quarter-over-quarter.
  • 6 funds opened new Protalix BioTherapeutics positions in Q3 2021 and 5 closed out, a net change of +1 holder.
  • The largest Protalix BioTherapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $643K added.
  • The largest Protalix BioTherapeutics seller in Q3 2021 was Bridgeway Capital Management, an estimated $509K sold.

Based on aggregated 13F filings for Q3 2021.